Herlander Marques
Overview
Explore the profile of Herlander Marques including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macauda A, Briem K, Clay-Gilmour A, Cozen W, Forsti A, Giaccherini M, et al.
Leukemia
. 2023 Sep;
37(11):2326-2329.
PMID: 37723249
No abstract available.
2.
Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela M, et al.
Int J Cancer
. 2022 Sep;
152(2):239-248.
PMID: 36082445
Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits....
3.
Fernandes M, Marques H, Teixeira A, Medeiros R
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740344
Non-Hodgkin lymphoma (NHL) is characterized by a great variability in patient outcomes, resulting in the critical need for identifying new molecular prognostic biomarkers. This study aimed to identify novel circulating...
4.
Fernandes M, Marques H, Teixeira A, Medeiros R
Int J Mol Sci
. 2022 Jan;
23(1).
PMID: 35008626
Research has been focusing on identifying novel biomarkers to better stratify non-Hodgkin lymphoma patients based on prognosis. Studies have demonstrated that lncRNAs act as miRNA sponges, creating ceRNA networks to...
5.
Fernandes M, Marques H, Teixeira A, Medeiros R
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944942
Increasing evidence has demonstrated the functional roles of miRNAs and lncRNAs in lymphoma onset and progression, either by acting as tumor-promoting ncRNAs or as tumor suppressors, emphasizing their appeal as...
6.
Fernandes M, Marques H, Teixeira A, Medeiros R
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944752
Non-Hodgkin lymphoma (NHL) is a heterogeneous malignancy with variable patient outcomes. There is still a lack of understanding about the different players involved in lymphomagenesis, and the identification of new...
7.
Canzian F, Piredda C, Macauda A, Zawirska D, Andersen N, Nagler A, et al.
Eur J Hum Genet
. 2021 Nov;
30(4):474-479.
PMID: 34845334
There is overwhelming epidemiologic evidence that the risk of multiple myeloma (MM) has a solid genetic background. Genome-wide association studies (GWAS) have identified 23 risk loci that contribute to the...
8.
Moura S, Abreu H, Cunha C, Ribeiro-Machado C, Oliveira C, Barbosa M, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771422
Multiple myeloma (MM) is the second most frequent hematological disease and can cause skeletal osteolytic lesions. This study aims to evaluate the expression of circulating microRNAs (miRNAs) in MM patients...
9.
Giaccherini M, Macauda A, Orciuolo E, Rymko M, Gruenpeter K, Dumontet C, et al.
Blood Cancer J
. 2021 Apr;
11(4):74.
PMID: 33854038
Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including...
10.
Macauda A, Piredda C, Clay-Gilmour A, Sainz J, Buda G, Markiewicz M, et al.
Int J Cancer
. 2021 Mar;
149(2):327-336.
PMID: 33675538
Gene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs)...